An anti-aging composition comprising: pinebark extract, polypodium leucotomos, ashwagandha extract, dehydroepiandrosterone, white tea extract, alpha lipoic acid, vitamin K2, bioactive silicon, hyaluronic acid, trimethylglycine, and optionally, piperine, green tea extract, folic acid, vitamin C, camu camu, and blueberry extract.

Pure saponins and processes for making such saponins are described herein. In addition, cosmetic compositions, such as skin care compositions, comprising such saponins and methods for improving skin health and appearance with such skincare compositions are also described herein.

Disclosed herein are pharmaceutical compositions and uses thereof in treating Parkinson’s disease. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., LeonurusjaponicusHoutt, Capsicum annuum L., Lophatherum gracile Brongn, Cur-cuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

Disclosed herein are pharmaceutical compositions and uses thereof in treating Parkinson’s disease. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., LeonurusjaponicusHoutt, Capsicum annuum L., Lophatherum gracile Brongn, Cur-cuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

Disclosed herein are pharmaceutical compositions and uses thereof in treating Parkinson’s disease. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., LeonurusjaponicusHoutt, Capsicum annuum L., Lophatherum gracile Brongn, Cur-cuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

A composition includes ashwagandha in a range of 5% to 20%; plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%; coffee fruit extract in a range of 0.5% to 10%; grape seed extract in a range of 1% to 10%; Cordyceps in a range of 5% to 20%; extended-release caffeine in a range of 0.5% to 10%; whole coffee fruit extract in a range of 1% to 10%; Schisandra extract in a range of 1% to 10%; L-theanine in a range of 1% to 10%; and beet juice in a range of 20% to 60%.

A composition includes ashwagandha in a range of 5% to 20%; plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%; coffee fruit extract in a range of 0.5% to 10%; grape seed extract in a range of 1% to 10%; Cordyceps in a range of 5% to 20%; extended-release caffeine in a range of 0.5% to 10%; whole coffee fruit extract in a range of 1% to 10%; Schisandra extract in a range of 1% to 10%; L-theanine in a range of 1% to 10%; and beet juice in a range of 20% to 60%.

A composition includes ashwagandha in a range of 5% to 20%; plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%; coffee fruit extract in a range of 0.5% to 10%; grape seed extract in a range of 1% to 10%; Cordyceps in a range of 5% to 20%; extended-release caffeine in a range of 0.5% to 10%; whole coffee fruit extract in a range of 1% to 10%; Schisandra extract in a range of 1% to 10%; L-theanine in a range of 1% to 10%; and beet juice in a range of 20% to 60%.

A method of producing plant-derived exosomes from plant tissue culture based cell suspension cultures is provided. The method includes: obtaining the plant tissue culture based cell suspension culture; mixing the the plant tissue culture based cell suspension culture with an isolation solution; centrifuging to obtain a supernatant and an infranatant; and obtaining the plant-derived exosomes from the infranatant. The objective of the present invention is to produce homogenous plant exosomes with high volume and purity by making use of the advantages of the plant suspension culture to be used for purposes such as therapeutics and drug carriers.

Provided is a protein having glucocerebrosidase activity and further having thermostability. The object is attained by a protein which is derived from a plant, belongs to glycoside hydrolase family 1 (GH1), and has glucocerebrosidase activity.